The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).
This guideline builds on past
Read Article
Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.
D2T-RA is defined by failure of at least two different mechanism of action
Read Article
Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.
Study of 63 Thalassemia pts (50
Links:
Links:
Dr. Jack Cush covers the news and journal reports from the past week on RheumNow.com. This week we have Insights NAFLD, overdose deaths, septic arthritis, refractory stills, & when MTX doesn’t work.
Read Article
Links:
What is the classic 'triad' of Still's disease? Does it affect males and females equally? What are typical lab findings? Which drugs are effective at treating Still's, and as importantly, which ones are not? What about complications? Read on for these and other FAQs regarding Still's disease.
Read Article
Links:
For 2022, let's look our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.
Read ArticleDr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.
Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast
Clear differences were apparent among the three major types of targeted medications for rheumatoid arthritis (RA) in a large European registry study.
For one, patients using inhibitors of the Janus-associated kinase (JAK) pathway were more likely to stop them because of adverse
Read ArticleDr. Jack Cush reviews the top abstracts from EULAR 2022 As chosen by me with the aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz. Speaking of social media
Read Article
For autoimmune patients with a history of malignancy, the initiation of biologic or targeted synthetic disease modifying agents (bDMARD/tsDMARDs) may provoke concern. While data for biologic medications and malignancy risk has been largely reassuring, clinical trials have often excluded
Read Article
Janet Pope @Janetbirdope( View Tweet )
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research (abstract OP0015)
Read Article
Links:
Links:
Aurelie Najm @AurelieRheumo( View Tweet )
